Tuesday June 27th 2017

Robust brain MRI denoising and segmentation using enhanced non‐local means algorithm

ABSTRACT Image denoising is an integral component of many practical medical systems. Non‐local means (NLM) is an effective method for image denoising which exploits the inherent structural redundancy present in images. Improved adaptive non‐local means (IANLM) is an improved variant of classical NLM based on a robust threshold criterion. In this paper, we have proposed an enhanced non‐local means (ENLM) algorithm, for application to brain MRI, by introducing several extensions to the IANLM algorithm. First, a Rician bias correction method is applied for adapting the IANLM algorithm to Rician noise in MR images. Second, a selective median filtering procedure based on fuzzy c‐means algorithm is proposed as a postprocessing step, in order to further improve the quality of IANLM‐filt…

Source:  

Robust brain MRI denoising and segmentation using enhanced non‐local means algorithm

Leave a Comment

More from category

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…
Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis
CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug
Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…
New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation
MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]